Moreover, a comprehensive screening study on 250 Indian breast cancer patients confirmed the association of the CYP2C19*2 allele with disease outcomes, particularly highlighting the gene-dose effect of CYP2C19*2 in relation to an increased risk of adverse reactions [102]. This evidence concerns the gene CYP2C19 and breast carcinoma.